GlycoNex Presents Preclinical Data on GNX1021 at AACR Annual Meeting 2025
Novel glycan-directed ADC shows preclinical activity in gastric cancer and potential to address underserved patient population
NEW TAIPEI CITY, Taiwan, April 28, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the presentation of preclinical data on GNX1021, its lead antibody-drug conjugate (ADC) program, at the American Association for Cancer Research (AACR) Annual Meeting 2025. The presentation is part of a poster session held on April 28, 2025, at McCormick Place in Chicago.
GNX1021 is a novel ADC that targets branched Lewis B/Y (bLeB/Y), a tumor-associated glycan highly expressed in gastric cancer and other solid tumors. The target has a distinct expression profile compared to HER2 and CLDN18—two well-known markers in gastric cancer—allowing GNX1021 to potentially treat patients who are not eligible for current HER2- or CLDN18-targeted therapies.
The poster presents preclinical data showing GNX1021's antitumor activity in gastric cancer models with high bLeB/Y expression, along with a favorable safety profile in nonclinical studies. Findings suggest that GNX1021 may offer a differentiated therapeutic option for gastric cancer patients with limited targeted treatment choices.
"These data demonstrate the potential of GNX1021 to expand the treatment landscape for gastric cancer by targeting a glycan biomarker not addressed by existing therapies," said Dr. Mei-Chun Yang, CEO of GlycoNex. "As a first-in-class anti-glycan ADC, GNX1021 exemplifies our approach to developing next-generation oncology therapeutics designed to overcome tumor heterogeneity and drug resistance."
GlycoNex is advancing GNX1021 through IND-enabling preclinical development, with an IND submission planned for Q1 2026 and Phase 1 trial initiation expected in Q2 2026.
Presentation Details:
Event: | American Association for Cancer Research (AACR) Annual Meeting 2025 |
Session Category: | Experimental and Molecular Therapeutics |
Session: | Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 1 |
Abstract Title: (#2932) | GNX1021, a novel ADC targeting glycans with branched Lewis B/Y, demonstrated preclinical tumor control activity in gastric cancer models and favorable safety |
Date and Time: | April 28, 2025; 2:00 pm CDT |
Location: | McCormick Place Convention Center, Chicago Poster Section 17, Poster Board 6 |
About GlycoNex Inc.
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw.
Contacts for GlycoNex, Inc.
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
[email protected]
Media Relations
Eric Reiss
[email protected]
SOURCE GlycoNex, Inc.
Share this article